171 related articles for article (PubMed ID: 21969227)
1. No differences in the pharmacodynamics and pharmacokinetics of the thrombin receptor antagonist vorapaxar between healthy Japanese and Caucasian subjects.
Kosoglou T; Reyderman L; Kasserra C; Jennings LK; Young S; Xuan F; Pei J; Maxwell SE; Schiller J; Meehan AG; Cutler DL
Eur J Clin Pharmacol; 2012 Mar; 68(3):291-300. PubMed ID: 21969227
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects.
Kosoglou T; Reyderman L; Tiessen RG; van Vliet AA; Fales RR; Keller R; Yang B; Cutler DL
Eur J Clin Pharmacol; 2012 Mar; 68(3):249-58. PubMed ID: 21935705
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease.
Kosoglou T; Kraft WK; Kumar B; Statkevich P; Xuan F; Ma L; Jennings LK; Schiller JE; Langdon RB; Cutler DL
Eur J Clin Pharmacol; 2012 Jul; 68(7):1049-56. PubMed ID: 22315147
[TBL] [Abstract][Full Text] [Related]
4. No Pharmacokinetic Drug-Drug Interaction Between Prasugrel and Vorapaxar Following Multiple-Dose Administration in Healthy Volunteers.
Anderson MS; Kosoglou T; Statkevich P; Li J; Rotonda J; Meehan AG; Cutler DL
Clin Pharmacol Drug Dev; 2018 Feb; 7(2):143-150. PubMed ID: 28403576
[TBL] [Abstract][Full Text] [Related]
5. Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics and pharmacodynamics of warfarin.
Kosoglou T; Zhu Y; Xuan F; Black L; Johnson-Levonas AO; Martinho M; Statkevich P; Cutler DL
Eur J Clin Pharmacol; 2012 Nov; 68(11):1509-16. PubMed ID: 22476387
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of the novel PAR-1 antagonist vorapaxar in patients with hepatic impairment.
Statkevich P; Kosoglou T; Preston RA; Kumar B; Xuan F; Trusley C; Schiller JE; Langdon RB; Cutler DL
Eur J Clin Pharmacol; 2012 Nov; 68(11):1501-8. PubMed ID: 22527342
[TBL] [Abstract][Full Text] [Related]
7. Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease.
Arif SA; D'Souza J; Gil M; Gim S
Am J Health Syst Pharm; 2015 Oct; 72(19):1615-22. PubMed ID: 26386102
[TBL] [Abstract][Full Text] [Related]
8. Unmet needs in the management of acute myocardial infarction: role of novel protease-activated receptor-1 antagonist vorapaxar.
Cho JR; Rollini F; Franchi F; Ferrante E; Angiolillo DJ
Vasc Health Risk Manag; 2014; 10():177-88. PubMed ID: 24729713
[TBL] [Abstract][Full Text] [Related]
9. Effect of Vorapaxar Alone and in Combination with Aspirin on Bleeding Time and Platelet Aggregation in Healthy Adult Subjects.
Kraft WK; Gilmartin JH; Chappell DL; Gheyas F; Walker BM; Nagalla S; Naik UP; Horrow JC; Wrishko RE; Zhang S; Anderson MS
Clin Transl Sci; 2016 Aug; 9(4):221-7. PubMed ID: 27304196
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of vorapaxar and its metabolite following oral administration in healthy Chinese and American subjects.
Chen X; Kosoglou T; Statkevich P; Kumar B; Li J; Dockendorf MF; Wang G; Lowe RS; Jiang J; Liu H; Wang Z; Cutler DL; Hu P
Int J Clin Pharmacol Ther; 2014 Oct; 52(10):889-99. PubMed ID: 25138682
[TBL] [Abstract][Full Text] [Related]
11. Vorapaxar: a novel protease-activated receptor-1 inhibitor.
Gurbel PA; Jeong YH; Tantry US
Expert Opin Investig Drugs; 2011 Oct; 20(10):1445-53. PubMed ID: 21819272
[TBL] [Abstract][Full Text] [Related]
12. Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics of rosiglitazone.
Kosoglou T; Kumar B; Statkevich P; Schiller JE; Kantesaria B; Hanson ME; Sisk CM; Cutler DL
Clin Pharmacol Drug Dev; 2015 Jan; 4(1):56-62. PubMed ID: 27128003
[TBL] [Abstract][Full Text] [Related]
13. Review of vorapaxar for the prevention of atherothrombotic events.
Wang A
Expert Opin Pharmacother; 2015; 16(16):2509-22. PubMed ID: 26480240
[TBL] [Abstract][Full Text] [Related]
14. Vorapaxar for the reduction of atherothrombotic events.
Diaz-Ricart M; Escolar G
Drugs Today (Barc); 2014 Nov; 50(11):747-56. PubMed ID: 25525635
[TBL] [Abstract][Full Text] [Related]
15. In vitro pharmacological characterization of vorapaxar, a novel platelet thrombin receptor antagonist.
Hawes BE; Zhai Y; Hesk D; Wirth M; Wei H; Chintala M; Seiffert D
Eur J Pharmacol; 2015 Sep; 762():221-8. PubMed ID: 26022529
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic drug evaluation of vorapaxar for secondary prevention after acute coronary syndrome.
Perez-Rivera JA; Monedero-Campo J; Cieza-Borrella C; Ruiz-Perez P
Expert Opin Drug Metab Toxicol; 2017 Mar; 13(3):339-350. PubMed ID: 28135897
[TBL] [Abstract][Full Text] [Related]
17. Vorapaxar in the secondary prevention of atherothrombosis.
Tantry US; Liu F; Chen G; Gurbel PA
Expert Rev Cardiovasc Ther; 2015 Dec; 13(12):1293-305. PubMed ID: 26559689
[TBL] [Abstract][Full Text] [Related]
18. Safety of the novel protease-activated receptor-1 antagonist vorapaxar in Japanese patients with a history of ischemic stroke.
Shinohara Y; Goto S; Doi M; Jensen P
J Stroke Cerebrovasc Dis; 2012 May; 21(4):318-24. PubMed ID: 20947374
[TBL] [Abstract][Full Text] [Related]
19. PAR1 antagonists inhibit thrombin-induced platelet activation whilst leaving the PAR4-mediated response intact.
Judge HM; Jennings LK; Moliterno DJ; Hord E; Ecob R; Tricoci P; Rorick T; Kotha J; Storey RF
Platelets; 2015; 26(3):236-42. PubMed ID: 24750101
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Protease-Activated Receptor (PAR1) Reduces Activation of the Endothelium, Coagulation, Fibrinolysis and Inflammation during Human Endotoxemia.
Schoergenhofer C; Schwameis M; Gelbenegger G; Buchtele N; Thaler B; Mussbacher M; Schabbauer G; Wojta J; Jilma-Stohlawetz P; Jilma B
Thromb Haemost; 2018 Jul; 118(7):1176-1184. PubMed ID: 29864779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
